A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer Clinical Trial Results and Information

A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

ClinicalTrials.gov processed this data on October 23, 2024. Link to the current ClinicalTrials.gov record.

Recruitment Status

ACTIVE, NOT RECRUITING (See Contacts and Locations)
Verified October 2024 by Janssen Research & Development, LLC

Sponsor

Janssen Research & Development, LLC

Information Provided by (Responsible Party)

Janssen Research & Development, LLC

Clinicaltrials.gov Identifier

NCT05388669
Other Study ID Numbers: CR109211
First Submitted: May 19, 2022
First Posted: May 24, 2022
Last Update Posted: October 24, 2024
Last Verified: October 2024
History of Changes

Disclaimer

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

Not Provided

Condition or Disease	Intervention/Treatment
Advanced or Metastatic Non-small Cell Lung Cancer	Drug: Lazertinib Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) Drug: Amivantamab Intravenous

Study Design

Study Type	Interventional
Actual Enrollment	418 participants
Design Allocation	Randomized
Interventional Model	Parallel Assignment
Masking	None (Open Label)
Primary Purpose	Treatment
Official Title	A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy
Study Start Date	August 5, 2022
Actual Primary Completion Date	January 3, 2024
Anticipated Study Completion Date	December 31, 2025

Groups and Cohorts

Group/ Cohort	Intervention/ Treatment
Arm A: Lazertinib with Amivantamab SC-CF Lazertinib 240 milligrams (mg) will be administered orally once daily. Participants will receive amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), 1600 mg/ 2240 mg depending on the body weight by manual injection. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the long-term extension (LTE) Phase.	Drug: Lazertinib Lazertinib tablets will be administered orally. Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
Arm B: Lazertinib with Amivantamab Intravenous (IV) Infusion Lazertinib 240 mg will be administered orally once. Participants will receive amivantamab, 1050 mg or 1400 mg depending on the body weight as an IV infusion. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the LTE Phase.	Drug: Lazertinib Lazertinib tablets will be administered orally. Drug: Amivantamab Intravenous

Outcome Measures

Primary Outcome Measures

For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State on Cycle 4 Day 1 [Cycle 4 Day 1 (28 days cycle)]
Ctrough is the observed serum concentration of Amivantamab at steady state on Cycle 4 Day 1 immediately prior to the next drug administration.
For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab at Pre-dose on Cycle 2 Day 1 [Cycle 2 Day 1 (28 days cycle)]
Ctrough is the observed serum concentration of Amivantamab at pre-dose on Cycle 2 Day 1 immediately prior to the next drug administration.
Area Under the Concentration Time Curve from Day 1 to Day 15 (AUC[Day 1-15]) of Amivantamab of Cycle 2 [Cycle 2 Day 1 to Cycle 2 Day 15 (28 days cycle)]
AUC(Day 1-15) defined as area under the concentration time curve from Cycle 2 Day 1 to Day 15, will be reported.

Secondary Outcome Measures

Objective Response Rate (ORR) [Up to 1 year 11 months]
ORR is defined as the percentage of participants who achieve either a CR or PR as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST version 1.1).
Progression-Free Survival (PFS) [Up to 1 year 11 months]
PFS is defined as the time from randomization until the date of objective disease progression or death, whichever comes first, based on RECIST version 1.1.
Duration of Response (DOR) [Up to 1 year 11 months]
The DoR is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR.
Time to Response (TTR) [Up to 1 year 11 months]
Time to response (that is time to first response) is defined as the time from the date of randomization to the date of first documentation of a response (PR or CR) prior to any disease progression and subsequent anticancer therapy, as defined by BICR using RECIST version 1.1., for participants who have PR or CR as their best response.
Number of Participants With Adverse Events (AEs) [Up to 4 year 11 months]
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
Number of Participants with AEs by Severity [Up to 4 year 11 months]
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
Number of Participants with Clinical Laboratory Abnormalities [Up to 4 year 11 months]
Number of participants with clinical laboratory abnormalities (serum Chemistry, hematology, coagulation, and urinalysis) will be reported. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
Number of Participants with Clinical Laboratory Abnormalities by Severity [Up to 4 year 11 months]
Number of participants with clinical laboratory abnormalities by severity (serum Chemistry, hematology, coagulation, and urinalysis) will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
Number of Participants Infusion Related Reactions (IRRs) [Up to 1 year 11 months]
Number of participants with IRRs will be reported.
Number of Participants with Infusion Related Reactions (IRRs) by Severity [Up to 1 year 11 months]
Number of participants with IRRs by severity will be reported.
For All Regions Other Than the EU and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Pre-dose on Cycle 2 Day 1 [Cycle 2 Day 1 (28 days cycle)]
The Ctrough is the observed serum concentration of Amivantamab at pre-dose on Cycle 2 Day 1 immediately prior to the next drug administration.
For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State on Cycle 4 Day 1 [Cycle 4 Day 1 (28 days cycle)]
The Ctrough is the observed serum concentration of Amivantamab at steady state on Cycle 4 Day 1 immediately prior to the next drug administration.
Model-Predicted Area Under the Concentration Time Curve from Day 1 to Day 15 (AUC[Day 1-15]) of Amivantamab at Steady State of Cycle 4 [From Cycle 4 Day 1 to Cycle 4 Day 15 (28 days cycle)]
Model-predicted AUC(Day 1-15) defined as area under the concentration time curve from Cycle 4 Day 1 to Day 15, will be reported.
Percentage of Participants with Presence of Anti-amivantamab Antibodies and Anti-rHuPH20 Antibodies [Up to 1 year 11 months]
Percentage of participants with presence of anti-amivantamab antibody anti-rHuPH20 antibodies will be reported.
Percentage of Participants with Cancer Therapy Satisfaction as Assessed by Therapy Administration Satisfaction Questionnaire (TASQ) [Up to 1 year 11 months]
Percentage of participants with cancer therapy satisfaction in will be assessed using the modified TASQ. The modified TASQ is an 11-item questionnaire measuring the impact of each mode of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction.
Change from Baseline in TASQ as Assessed Over Time [Up to 1 year 11 months]
Change from baseline in TASQ as assessed Over time will be reported. The modified TASQ is an 11-item questionnaire measuring the impact of each mode of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction.
Participant Chair Time [Up to 1 year 11 months]
Participant chair time will be assessed by time and motion analysis.
Duration of Treatment Administration [Up to 1 year 11 months]
Duration of treatment administration will be assessed by time and motion analysis.
Active HCP Time For Drug Preparation, Treatment Administration and Posttreatment Monitoring [Up to 1 year 11 months]
Active health care professional time for drug preparation, treatment administration, and posttreatment monitoring will be assessed by time and motion analysis.
Participant Time in Treatment Room [Up to 1 year 11 months]
Participant time in treatment room will be assessed by time and motion analysis.

Eligibility Criteria

Ages Eligible for Study	18 Years and Older (Adult, Older Adult)
Sexes Eligible for Study	All
Accepts Healthy Volunteers	No
Inclusion Criteria	Have histologically or cytologically confirmed, advanced or metastatic non-small cell lung cancer (NSCLC), characterized by either epidermal growth factor receptor (EGFR) Exon 19 deletion (Exon 19del) or Exon 21 leucine 858 to arginine substitution (Exon 21 L858R) mutation by an Food and Drug Administration (FDA)-approved or other validated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United Started [US]) or an accredited local laboratory (sites outside of the US) Have progressed on or after osimertinib (or another approved 3rd generation epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor [TKI]) and platinum-based chemotherapy (irrespective of order). a) The 3rd generation EGFR TKI must have been administered as the first EGFR TKI for metastatic disease or as the second TKI after prior treatment with first- or second-generation EGFR TKI in participants with metastatic EGFR T790M mutation positive NSCLC. b) Participants who decline or are otherwise ineligible for chemotherapy may be enrolled after discussion with the medical monitor. c) Any adjuvant or neoadjuvant treatment, whether with a 3rd generation EGFR TKI or platinum based chemotherapy, would count towards the prior treatment requirement if the participant experienced disease Have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) version 1.1 Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Version 5.0 Grade 1 or baseline level (except for alopecia [any grade], Grade less than or equal to (<=) 2 peripheral neuropathy, and Grade <=2 hypothyroidism stable on hormone replacement)
Exclusion Criteria	Participant has received cytotoxic, investigational, or targeted therapies beyond one regimen of platinum-based chemotherapy and EGFR inhibitors Participant has received radiotherapy for palliative purposes less than 7 days prior to randomization Participant has symptomatic or progressive brain metastases Participant has leptomeningeal disease, or participant has spinal cord compression not definitively treated with surgery or radiation Participant has uncontrolled tumor-related pain Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis

Contacts and Locations

Sponsors and Collaborators	Janssen Research & Development, LLC
Locations	City of Hope Duarte \| Duarte, California, United States, 91010 City of Hope Orange County Lennar Foundation Cancer Center \| Irvine, California, United States, 92618 City of Hope Long Beach Elm \| Long Beach, California, United States, 90813 National Jewish Health \| Denver, Colorado, United States, 80206 Baptist Lynn Cancer Institute \| Boca Raton, Florida, United States, 33486 Orlando Health \| Orlando, Florida, United States, 32806 University of Kansas \| Kansas City, Kansas, United States, 66160 University of Michigan \| Ann Arbor, Michigan, United States, 48109 Astera Cancer Care \| East Brunswick, New Jersey, United States, 08816 Rutgers Cancer Institute of New Jersey \| New Brunswick, New Jersey, United States, 08901 Montefiore Medical Center \| Bronx, New York, United States, 10461 NYU Langone Health Laura and Isaac Perlmutter Cancer Center \| New York, New York, United States, 10016 Providence Portland Medical Center \| Portland, Oregon, United States, 97213 Providence Oncology and Hematology Care Clinic Westside \| Portland, Oregon, United States, 97225 University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine \| Philadelphia, Pennsylvania, United States, 19104 Medical University of South Carolina \| Charleston, South Carolina, United States, 29425 Virginia Cancer Specialists \| Fairfax, Virginia, United States, 22031 CEMIC (Centro de Educación Médica e Investigaciones Clínicas) \| Buenos Aires, Argentina, 1431 IADT Instituto Argentino de Diagnostico y Tratamiento \| Caba, Argentina, C1122 Centro Oncológico Korben \| Ciudad Autonoma de Buenos Aires, Argentina, C1426AGE Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica \| Cordoba, Argentina, 5000 Sanatorio Allende \| Cordoba, Argentina, 5000 Clínica Viedma \| Viedma, Argentina, R8500ACE Cancer Research SA \| Adelaide, Australia, 5000 Chris O'Brien Lifehouse \| Camperdown, Australia, 2050 Peter MacCallum Cancer Centre \| Melbourne, Australia, 3000 St John of God Hospital Murdoch \| Murdoch, Australia, 6150 Westmead Hospital \| Westmead, Australia, 2145 Princess Alexandra Hospital \| Woolloongabba, Australia, 4102 Fundacao Pio XII \| Barretos, Brazil, 14784-400 Cetus Oncologia \| Belo Horizonte, Brazil, 30110-017 Instituto Cionc de Ensino e Pesquisa S/S \| Curitiba, Brazil, 80810-050 Ynova Pesquisa Clinica \| Florianopolis, Brazil, 88020-210 Fundacao Sao Francisco Xavier HMC Unidade de Oncologia \| Ipatinga, Brazil, 35162 189 UPCO Unidade de Pesquisa Clinica em Oncologia \| Pelotas, Brazil, 96020 080 Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS \| Porto Alegre, Brazil, 90610-000 Impar Servicos Hospitalares S/A \| Rio de Janeiro, Brazil, 22061-080 Oncoclinicas Rio de Janeiro S A \| Rio de Janeiro, Brazil, 22250 905 Instituto D Or de Pesquisa e Ensino IDOR \| Rio de Janeiro, Brazil, 22281 100 Nucleo de Oncologia da Bahia \| Salvador, Brazil, 40170 110 CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia \| Santo Andre, Brazil, 09060-650 Impar Servicos Hospitalares SA Hospital Nove de Julho \| Sao Paulo, Brazil, 01409-002 Onco Star SP Oncologia Ltda \| Sao Paulo, Brazil, 04543-000 Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein \| Sao Paulo, Brazil, 05652 900 Núcleo de Pesquisa São Camilo \| São Paulo, Brazil, 04014-002 The Ottawa Hospital Cancer Centre \| Ottawa, Ontario, Canada, K1H 8L6 Princess Margaret Hospital \| Toronto, Ontario, Canada, M5G 1Z5 Beijing Shijitan Hospital, Capital Medical University \| Beijing, China, 100038 Beijing Friendship Hospital Capital Medical University \| Beijing, China, 100050 Peking University Third Hospital \| Beijing, China, 100191 Beijing Chest hospital, Capital medical university \| Beijing, China, 101149 Cancer Hospital Chinese Academy of Medical Sciences \| Beijing, China, 200240 Jilin cancer hospital \| Changchun, China, 130012 The First People's Hospital Of Changzhou \| Changzhou, China, 213004 Sichuan Cancer Hospital \| Chengdu, China, 610041 West China Hospital Sichuan University \| Chengdu, China, 610047 Chongqing University Cancer Hospital \| Chongqing, China, 400030 Southwest Hospital \| ChongQing, China, 400038 First Affiliated Hospital of Gannan Medical University \| Ganzhou, China, 341000 The First Affiliated Hospital Sun Yat sen University \| Guang Zhou, China, 510080 Sun Yat-Sen Memorial Hospital Sun Yat-sen University \| Guangzhou, China, 510000 Zhejiang Cancer Hospital \| Hang Zhou, China, 310022 The Second Affiliated Hospital of Zhejiang University College of Medicine \| Hangzhou, China, 310009 Sir Run Run Shaw Hospital, Zhejiang University School of Medicine \| Hangzhou, China, 310016 Harbin medical university cancer hospital \| Harbin, China, 150081 Huizhou Municipal Central Hospital \| Huizhou, China, 516001 Huizhou First Hospital \| Huizhou, China, 516003 Liuzhou people's Hospital \| Liuzhou, China, 545026 Affiliated Hospital of North Sichuan Medical College \| Nanchong, China, 637100 Fudan University Shanghai Cancer Center \| Shanghai, China, 200032 Shenzhen People s Hospital \| Shen Zhen Shi, China, 518001 Shengjing Hospital Of China Medical University \| Shenyang, China, 110004 Shenzhen university General Hospital \| Shenzhen, China, 518055 Tianjin Medical University Cancer Institute and Hospital \| Tianjin, China, 300060 Union Hospital Tongji Medical College of Huazhong University of Science and Technology \| Wuhan, China, 430022 The First Affiliated Hospital of Xian Jiaotong University \| XI An, China, 710061 Xiangyang Central Hospital \| Xiangyang, China, 441021 Yantai Yuhuangding Hospital \| Yantai, China, 264000 Henan Cancer Hospital \| Zhengzhou, China, 450008 CHU Grenoble \| La Tronche, France, 38700 Institute Coeur Poumon \| Lille, France, 59000 CHU de Limoges Hopital Dupuytren \| Limoges, France, 87000 Hopital Nord \| Marseille Cedex 20, France, 13915 Evangelische Lungenklinik Berlin \| Berlin, Germany, 13125 Niels-Stensen-Kliniken Franziskus-Hospital Harderberg \| Georgsmarienhütte, Germany, 49124 Universitaetsklinikum Giessen und Marburg GmbH \| Giessen, Germany, 35392 Munster University Hospital \| Münster, Germany, 48149 Oncologianova GmbH \| Recklinghausen, Germany, 45659 Onkologische Schwerpunktpraxis \| Weinsberg, Germany, 74189 Rambam Medical Center \| Haifa, Israel, 3109601 Shaare Zedek Medical Center \| Jerusalem, Israel, 91031 Meir Medical Center \| Kfar Saba, Israel, 44281 Rabin Medical Center \| Petah-Tikva, Israel, 49100 Chaim Sheba Medical Center \| Ramat Gan, Israel, 5262100 Oncologia Medica - Irccs - Istituto Tumori Giovanni Paolo II \| Bari, Italy, 70124 A O U Sant Orsola Malpighi \| Bologna, Italy, 40138 European Institute of Oncology \| Milano, Italy, 20141 Aou San Luigi Gonzaga \| Orbassano, Italy, 10043 Istituto Oncologico Veneto - IRCCS \| Padova, Italy, 35128 Ospedale S. Maria Delle Croci \| Ravenna, Italy, 48121 A.O. San Camillo Forlanini \| Roma, Italy, 00152 Istituto Nazionale Tumori Regina Elena \| Rome, Italy, 00144 Istituto Clinico Humanitas \| Rozzano, Italy, 20089 National Cancer Center Hospital \| Chuo Ku, Japan, 104 0045 National Hospital Organization Himeji Medical Center \| Himeji, Japan, 670-8520 Kansai Medical University Hospital \| Hirakata, Japan, 573-1191 Kanagawa Cancer Center \| Kanagawa, Japan, 241-8515 Kurashiki Central Hospital \| Kurashiki, Japan, 710-8602 Kurume University Hospital \| Kurume, Japan, 830-0011 Matsusaka Municipal Hospital \| Matsusaka, Japan, 515-8544 Niigata Cancer Center Hospital \| Niigata, Japan, 951-8566 Okayama University Hospital \| Okayama, Japan, 700-8558 Osaka International Cancer Institute \| Osaka City, Japan, 541 8567 Hokkaido University Hospital \| Sapporo-shi, Japan, 060-8648 Shizuoka Cancer Center \| Shizuoka, Japan, 411 8777 The Cancer Institute Hospital of JFCR \| Tokyo, Japan, 135 8550 Fujita Health University Hospital \| Toyoake, Japan, 470-1192 National Hospital Organization Osaka Toneyama Medical Center \| Toyonaka-shi, Japan, 560-8552 Wakayama Medical University Hospital \| Wakayama, Japan, 641 8510 National Hospital Organization Iwakuni Clinical Center \| Yamaguchi, Japan, 740-8510 National Hospital Organization Yamaguchi Ube Medical Center \| Yamaguchi, Japan, 755-0241 National Cancer Center \| Gyeonggi-do, Korea, Republic of, 10408 CHA Bundang Medical Center, CHA University \| Gyeonggi-do, Korea, Republic of, 13496 GyeongSang National University Hospital \| Gyeongsangnam-do, Korea, Republic of, 52727 Chonnam National University Hwasun Hospital \| Jeollanam-do, Korea, Republic of, 58128 Seoul National University Bundang Hospital \| Seongnam-si, Korea, Republic of, 13620 Seoul National University Hospital \| Seoul, Korea, Republic of, 03080 Severance Hospital Yonsei University Health System \| Seoul, Korea, Republic of, 03722 Asan Medical Center \| Seoul, Korea, Republic of, 05505 Samsung Medical Center \| Seoul, Korea, Republic of, 06351 Prince Court Medical Centre \| Kuala Lumpur, Malaysia, 50450 Pantai Hospital Kuala Lumpur \| Kuala Lumpur, Malaysia, 59100 University Malaya Medical Centre \| Kuala Lumpur, Malaysia, 59100 Hospital Umum Sarawak \| Kuching, Malaysia, 93586 Beacon Hospital Sdn Bhd \| Petaling Jaya, Malaysia, 46050 Sunway Medical Centre \| Petaling Jaya, Malaysia, 47500 Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy \| Bydgoszcz, Poland, 85-796 Krakowski Szpital Specjalityczny im. Jana Pawla II \| Krakow, Poland, 31-202 Mazowieckie Centrum Leczenia Chorob Pluc \| Otwock, Poland, 05-400 Private Specialist Hospitals - MedPolonia \| Poznan, Poland, 60-693 Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy \| Warszawa, Poland, 02-781 Hospital de Braga \| Braga, Portugal, 4710-243 Hospital da Luz, SA \| Lisboa, Portugal, 1500-650 Hosp. Cuf Descobertas \| Lisboa, Portugal, 1998-018 Hospital Pedro Hispano \| Senhora da Hora,, Portugal, 4464-513 Hosp Univ A Coruna \| A Coruna, Spain, 15006 Hosp. Gral. Univ. de Alicante \| Alicante, Spain, 03010 Hosp Univ Vall D Hebron \| Barcelona, Spain, 08035 Hosp Clinic de Barcelona \| Barcelona, Spain, 08036 Hosp. Univ. Quiron Dexeus \| Barcelona, Spain, 8028 Hosp Reina Sofia \| Córdoba, Spain, 14004 Hosp. Univ. Insular de Gran Canaria \| Las Palmas de Gran Canaria, Spain, 35016 Hosp. Univ. Lucus Augusti \| Lugo, Spain, 27003 Hosp. Gral. Univ. Gregorio Maranon \| Madrid, Spain, 28009 Hosp. Univ. La Paz \| Madrid, Spain, 28046 Hosp. Univ. Pta. de Hierro Majadahonda \| Majadahonda, Spain, 28222 Hosp Regional Univ de Malaga \| Málaga, Spain, 29011 Hosp. Univ. Central de Asturias \| Oviedo, Spain, 33011 Hosp. Univ. Son Espases \| Palma de Mallorca, Spain, 07120 Hosp. Virgen Del Rocio \| Sevilla, Spain, 41013 Hosp. Univ. I Politecni La Fe \| Valencia, Spain, 46026 Changhua Christian Hospital \| Changhua, Taiwan, 50006 Chang Kung Memorial Hospital \| Kaohsiung City, Taiwan, 833 Kaohsiung Medical University Chung Ho Memorial Hospital \| Kaohsiung, Taiwan, 80756 Chung Shan Medical University Hospital \| Taichung, Taiwan, 403 National Cheng Kung University Hospital \| Tainan, Taiwan, 70403 National Taiwan University Cancer Center \| Taipei City, Taiwan, 106 National Taiwan University Hospital \| Taipei, Taiwan, 10048 Linkou Chang Gung Memorial Hospital \| Taoyuan, Taiwan, 33382 Phramongkutklao Hospital and Medical College \| Bangkok, Thailand, 10400 Siriraj Hospital \| Bangkok, Thailand, 10700 Chiang Mai University \| Chiangmai, Thailand, 50200 Adana City Hospital \| Adana, Turkey, 01060 Adana Baskent Hospital \| Adana, Turkey, 01120 Memorial Ankara Hastanesi \| Ankara, Turkey, 06520 Gazi University Hospital \| Ankara, Turkey, 06560 Ankara Bilkent City Hospital \| Ankara, Turkey, 06800 Trakya University Medical Faculty \| Edirne, Turkey, 22030 Istanbul University Cerrahpasa Medical Faculty \| Istanbul, Turkey, 34098 Acıbadem Maslak Hospital \| Istanbul, Turkey, 34457 Dokuz Eylul University Medical Faculty \| Izmir, Turkey, 35330 IEU Medical Point Hospital \| Izmir, Turkey, 35575 Medical Park Samsun Hastanesi \| Samsun, Turkey, 55200 Birmingham Heartlands Hospital \| Birmingham, United Kingdom, B9 5SS Imperial College Healthcare \| London, United Kingdom, W2 1NY Newcastle Freeman Hospital \| Newcastle Upon Tyne, United Kingdom, NE7 7DN Royal Marsden Hospital \| Sutton, United Kingdom, SM2 5PT
Investigators

More Information

Additional Relevant MeSH Terms

Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms